Cagrilintide (originally designated AM833) is a long-acting, fatty-acid–acylated analog of human amylin that has become one of the most closely watched compounds in metabolic peptide research. Because it engages the amylin and calcitonin receptor system rather than the incretin pathway targeted by GLP-1 analogs, cagrilintide occupies a mechanistically distinct niche in the satiety-signaling literature. This review summarizes its structure, receptor pharmacology, and the published preclinical and clinical evidence. All content is provided strictly for research reference and is not intended for human or veterinary use.
What is cagrilintide? Cagrilintide is a synthetic long-acting analog of human amylin (islet amyloid polypeptide) engineered with a C20 fatty-diacid side chain that binds reversibly to albumin. It acts as a dual agonist of the amylin receptors (calcitonin receptor complexed with RAMP proteins) and the calcitonin receptor itself, and in research models it engages hindbrain satiety circuits with a plasma half-life of roughly 7–9 days [1,3].
Key research findings at a glance
- Cagrilintide is an acylated amylin analog acting as a dual amylin (AMY1/AMY3) and calcitonin receptor agonist [1,5].
- A C20 fatty-diacid modification confers >99% reversible albumin binding and a ~7–9 day half-life, versus roughly 4 minutes for native amylin [1,3].
- Preclinical weight-reducing effects depend on amylin receptors 1 and 3 in the hindbrain dorsal vagal complex [4].
- Amylin signaling is mechanistically complementary to—not overlapping with—the GLP-1 pathway [3,6].
- The most mature clinical dataset is the combination program with semaglutide reported in phase 1b and phase 2 trials [3,6].
- All findings summarized here derive from preclinical and clinical studies and are research-use-only.
Introduction
Amylin is a 37–amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Its physiological role in slowing gastric emptying, suppressing postprandial glucagon, and signaling satiety made it an attractive research target, but native amylin is impractical as a laboratory probe: it aggregates readily into amyloid fibrils and is cleared from circulation within minutes [2,3]. Cagrilintide was engineered specifically to overcome those liabilities while preserving amylin's receptor pharmacology, and as a result it has become a widely referenced tool for studying amylin-receptor biology under conditions that permit sustained, once-weekly exposure in animal models [1,3].
The compound is best known in the clinical literature through its combination with the GLP-1 receptor agonist semaglutide—an investigational pairing studied in dose-finding trials—but the broader research interest spans receptor structural biology, hindbrain satiety circuitry, and glucose homeostasis [3,4,6]. This review treats each domain in turn and then situates cagrilintide against the amylin and calcitonin peptides most often discussed alongside it.
Amylin and the satiety axis
Amylin signaling is organized around the calcitonin receptor (CTR), a class B G-protein-coupled receptor. When CTR associates with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), it forms the high-affinity amylin receptor complexes designated AMY1, AMY2, and AMY3 [1,3]. These receptors are densely expressed in the hindbrain—particularly the area postrema and the nucleus of the solitary tract—regions positioned outside the blood–brain barrier and well placed to translate circulating metabolic signals into changes in feeding behavior [3,4].
Two features of this system are central to interpreting cagrilintide research. First, amylin signaling is anatomically distinct from incretin signaling: GLP-1 receptors and amylin receptors occupy overlapping but separable neural circuits, which is why the two pathways are reported to be additive rather than redundant when studied together [3,6]. Second, amylin's effects on satiety are thought to involve hedonic as well as homeostatic feeding pathways, a mechanistic contrast that has driven interest in amylin analogs as complementary research tools rather than substitutes for incretin-based compounds [6].
Structure and mechanism of action
Cagrilintide is a synthetic peptide built on an amylin-like backbone with substitutions that suppress the fibril-forming tendency of native human amylin, drawing in part on the more soluble sequence of salmon calcitonin–family peptides [1,3]. Its defining feature is an N-terminal acylation: a γGlu linker connects the peptide to a C20 fatty-diacid chain. This lipid moiety promotes reversible, high-affinity binding to serum albumin—reported at greater than 99%—which extends the functional half-life from the minutes of native amylin to roughly 7–9 days in pharmacokinetic studies [1,3].
Mechanistically, cagrilintide behaves as a dual amylin and calcitonin receptor agonist (a DACRA). It binds and activates the calcitonin receptor directly and, through the RAMP-complexed AMY receptors, reproduces amylin-like signaling [1,5]. Recent cryo-electron-microscopy work has resolved the peptide's binding mode at these receptors, describing an amylin-like engagement with distinct conformational dynamics at the calcitonin-family receptors that researchers have linked to its sustained receptor occupancy [1]. Receptor activation raises intracellular cyclic AMP through Gs coupling and, in vivo, produces cFos activation in hindbrain neurons of the dorsal vagal complex—a mechanistic signature confirmed by knockout studies discussed below [4].
Evidence by research domain
The published evidence base for cagrilintide combines structural biology, rodent pharmacology, and early-phase clinical characterization. The table below summarizes the principal domains, the models in which they have been examined, the reported observations, and the maturity of the evidence.
| Research domain | Typical models | Reported findings | Evidence maturity |
|---|---|---|---|
| Receptor structural biology | Cryo-EM of CTR/RAMP complexes | Amylin-like binding mode; distinct calcitonin-receptor conformational dynamics [1] | High — recent structural studies |
| Receptor dependence | RAMP1/RAMP3 knockout mice | Body-weight and cFos responses depend on AMY1R and AMY3R [4] | High — genetic knockout evidence |
| Preclinical metabolic pharmacology | High-fat-diet rodents | Dose-dependent reductions in caloric intake and body weight [3,5] | Moderate–high |
| Receptor-balance comparison | DACRA comparison (cagrilintide vs. KBP-336) | Receptor-activation balance influences metabolic readouts [5] | Moderate |
| Combination pharmacology | Phase 1b/phase 2 clinical trials | Additive effect with semaglutide; gastrointestinal tolerability signals [3,6] | Moderate — early-phase trials |
Receptor pharmacology and structural basis
The clearest recent advance is structural. Cryo-EM reconstructions of cagrilintide bound to calcitonin and amylin receptor complexes describe an amylin-like "bypass" engagement of the receptor while inducing conformational dynamics that differ from native peptides and from pramlintide [1]. Researchers have connected these features to the compound's prolonged receptor occupancy—a structural rationale for why an acylated, albumin-binding analog produces more sustained signaling than short-acting amylin mimetics [1].
Receptor dependence in knockout models
A 2025 study using RAMP1/RAMP3 knockout mice provided direct genetic evidence that cagrilintide's weight-reducing effect operates through amylin receptors 1 and 3. In animals lacking these RAMPs, the ability of the compound to reduce body weight and to activate cFos-positive neurons in the dorsal vagal complex was significantly impaired, establishing AMY1R and AMY3R as the mechanistic backbone of its central activity [4]. This is the kind of causal, mechanism-anchoring evidence that distinguishes a well-characterized research compound.
Combination and receptor-balance studies
Preclinical comparisons of DACRAs—for example cagrilintide versus KBP-336—have examined how the balance of amylin- versus calcitonin-receptor activation shapes metabolic readouts, a question relevant to interpreting differences among amylin-class research tools [5]. In the clinical literature, dose-finding work established the pharmacokinetic profile supporting once-weekly exposure, and combination studies with semaglutide reported additive effects on body-weight endpoints, consistent with the complementary-pathway hypothesis [3,6]. These clinical observations are summarized here strictly as reported study outcomes, not as guidance.
Cagrilintide vs. related compounds
Because cagrilintide is frequently discussed alongside other amylin and metabolic peptides, a mechanistic comparison clarifies where it fits. The critical distinctions are structural (native vs. analog, short- vs. long-acting) and pharmacological (amylin/calcitonin receptor vs. incretin receptor).
| Compound | Class / receptor | Structural note | Distinguishing research feature |
|---|---|---|---|
| Cagrilintide | Amylin analog / DACRA (AMY + CTR) | Acylated C20 diacid, albumin-binding | Long half-life (~7–9 d); knockout-confirmed AMY1/3 mechanism [1,4] |
| Native amylin | Endogenous amylin (AMY + CTR) | 37-aa peptide, fibril-prone | Half-life ~4 min; impractical as a probe [3] |
| Pramlintide | Amylin analog (AMY + CTR) | Short-acting synthetic analog | Requires frequent dosing; earlier-generation tool [1] |
| Semaglutide | GLP-1 receptor agonist | Acylated incretin analog | Distinct incretin pathway; studied in combination [3,6] |
| Tesamorelin | GHRH analog (GHRH-R) | Full-length GHRH(1–44) | Somatotropic-axis probe; see related review |
Cagrilintide vs. semaglutide
These two compounds are often compared because both have been studied for effects on body-weight endpoints, but they act on entirely different receptor systems. Cagrilintide is an amylin/calcitonin receptor agonist, whereas semaglutide-class molecules act at the GLP-1 receptor. Because the pathways are anatomically and mechanistically distinct, research designs frequently examine them together, and combination studies report additive effects—the basis of the investigational cagrilintide-plus-semaglutide program [3,6].
Cagrilintide vs. native amylin and pramlintide
All three engage the amylin/calcitonin receptor system, so the meaningful distinctions are structural and pharmacokinetic. Native amylin is fibril-prone and cleared within minutes; pramlintide is a short-acting synthetic analog requiring frequent administration; cagrilintide's acylation and albumin binding extend its half-life to roughly a week [1,3]. This short- versus long-acting distinction is central to interpreting the literature: cagrilintide's utility as a once-weekly research tool derives from a stabilizing modification rather than from a change in receptor target.
Limitations and research considerations
Early-stage clinical evidence. Much of the human data derives from early-phase (phase 1b/2) trials and combination programs; large confirmatory datasets for monotherapy are more limited than for longer-established compounds [3,6].
Tolerability signals. Reported clinical observations include gastrointestinal effects most pronounced during dose escalation. These are summarized as study observations, not use guidance [6].
Model translation. Much mechanistic detail rests on rodent and knockout models; extrapolation across species requires caution [4,5].
Receptor-balance nuance. Differences among DACRAs in amylin- versus calcitonin-receptor activation complicate direct cross-compound comparison [5].
Where to source for research
Reproducible peptide research depends on well-characterized, analytically verified material accompanied by certificates of analysis and mass-spectrometry / HPLC purity documentation. Among suppliers that catalog amylin-class reference compounds for laboratory use, Short Chain Aminos is a commonly referenced source that publishes third-party analytical data. Additional suppliers maintaining research-use catalogs in this class include BioPep, Catalyst Research, and Apex Research Services. As with any research material, laboratories should independently confirm identity, purity, and handling documentation rather than relying on catalog descriptions alone. For guidance on evaluating vendors, see our guide to evaluating research peptide suppliers.
Frequently asked research questions
What is cagrilintide studied for in research?
In the literature it is examined as a long-acting probe of amylin-receptor biology, with the most developed datasets addressing receptor structural biology, hindbrain satiety circuitry, and combination pharmacology with GLP-1 agonists. All such work is research-use-only and is not a basis for human or veterinary application [1,3,4].
How does cagrilintide differ from native amylin?
Native amylin aggregates into fibrils and is cleared within about four minutes. Cagrilintide carries substitutions that reduce aggregation plus a C20 fatty-diacid that binds albumin, extending its half-life to roughly 7–9 days while preserving amylin-receptor signaling [1,3].
What is a dual amylin and calcitonin receptor agonist?
A DACRA is a molecule that activates both the calcitonin receptor and the RAMP-complexed amylin receptors (AMY1–AMY3). Cagrilintide is described as a DACRA, and comparative studies suggest the balance of amylin- versus calcitonin-receptor activation shapes its metabolic readouts [1,5].
Why is cagrilintide studied alongside semaglutide?
Amylin and GLP-1 receptors occupy distinct neural circuits, so their signaling is reported to be additive rather than redundant. Early-phase trials examined the combination for this reason, observing complementary effects on body-weight endpoints [3,6].
Which receptors mediate cagrilintide's central effects?
Knockout studies in RAMP1/RAMP3-deficient mice showed that its body-weight and hindbrain cFos responses depend on amylin receptors 1 and 3, identifying AMY1R and AMY3R as the mechanistic backbone of its central activity [4].
Is cagrilintide a fragment or a full-length analog?
It is a full-length amylin-based analog rather than a truncated fragment, engineered with anti-aggregation substitutions and an acyl chain for albumin binding. Its stability comes from these modifications, not from shortening the peptide [1,3].
Works Cited
- Cryo-EM structural analysis of cagrilintide at calcitonin and amylin receptor complexes. Nature Communications. 2025;16. DOI: 10.1038/s41467-025-58680-y.
- Kruse T, Hansen JL, Dahl K, et al. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry. 2021;64(15). PMID: 34288673. DOI: 10.1021/acs.jmedchem.1c00565.
- Enebo LB, Berthelsen KK, Kankam M, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of cagrilintide with semaglutide 2·4 mg for weight management: a phase 1b trial." The Lancet. 2021;397(10286). PMID: 33894838. DOI: 10.1016/S0140-6736(21)00845-X.
- Carvas AO, Leuthardt A, Kulka P, et al. "Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3." EBioMedicine. 2025;118:105836. PMID: 40609154. DOI: 10.1016/j.ebiom.2025.105836.
- Larsen AT, Mohamed KE, Sonne N, et al. "Does receptor balance matter? Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models." Biomedicine & Pharmacotherapy. 2022;156:113842. PMID: 36242844. DOI: 10.1016/j.biopha.2022.113842.
- Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial." The Lancet. 2021;398(10317). PMID: 34798060. DOI: 10.1016/S0140-6736(21)01751-7.
Research Use Only. The information above summarizes published preclinical and clinical literature for laboratory reference. It is not medical advice and does not describe or endorse any human or veterinary use, dosing, or administration. Cagrilintide and related compounds discussed here are intended solely for in-vitro and research applications.
Explore related compounds: Tesamorelin · AOD-9604 · MOTS-c